Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Judd W. Moul, MD, FACS
Advertisement
Articles by Judd W. Moul, MD, FACS
Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
Advertisement
Latest Updated Articles
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial ExperiencePublished: May 13th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC
4
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
5
